Cullinan Therapeutics Inc.

News & Events

Press Releases

In The Media

1. Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

   GlobeNewswire JUN 4, 2025 4:02 PM EDT
   Advances Cullinan’s leadership in T cell engager (TCE) development for autoimmune diseases...
   READ ARTICLE

2. Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology

   PR Newswire JUN 1, 2025 8:21 AM EDT
   Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in ...
   READ ARTICLE

3. Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference

   GlobeNewswire MAY 29, 2025 7:00 AM EDT
   CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM;...
   READ ARTICLE

4. Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

   GlobeNewswire MAY 22, 2025 5:15 PM EDT
   CAMBRIDGE, Mass. and TOKYO, Japan and PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Cullina...
   READ ARTICLE

5. Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

   GlobeNewswire MAY 8, 2025 7:00 AM EDT
   Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in acti...
   READ ARTICLE

6. Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren's Disease in the United States

   GlobeNewswire APR 29, 2025 7:00 AM EDT
   CLN-978 is the first and only development-stage CD19 T cell engager to receive U.S. FDA IND clear...
   READ ARTICLE

7. Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025

   GlobeNewswire APR 23, 2025 10:14 AM EDT
   CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGE...
   READ ARTICLE

8. Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

   GlobeNewswire APR 16, 2025 7:00 AM EDT
   Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Unive...
   READ ARTICLE

9. Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

   GlobeNewswire FEB 27, 2025 7:00 AM EST
   Initial clinical data from global Phase 1 study of CLN-978 in Systemic Lupus Erythematosus (SLE) ...
   READ ARTICLE

10. Cullinan Therapeutics to Participate in Upcoming Investor Conferences

    GlobeNewswire FEB 24, 2025 7:00 AM EST
    CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM...
    READ ARTICLE